N-Acetyl Selank Amidate serves as a valuable research tool for investigating enhanced anxiolytic mechanisms, prolonged cognitive modulation, and sustained neurotransmitter system effects in laboratory settings.

Research Disclaimer: Peptides.GG sells this and all other peptides for Research Only and not for human consumption.

NA Selank Amidate

$40.00$65.00

Quantity
Price
<5
$40.00
5 - 9
$37.60 each (save $2.40 per unit)
10+
$35.20 each (save $4.80 per unit)
× NA Selank Amidate

Quantity

  • In stock. Order in the next 4h 20m 23s for delivery on Sunday, September 29
  • Free Delivery on all orders over $200
  • Earn 5% Store Credit with Every Order
  • Same Day Shipping Before 1 PM PST
  • 10% Discount for Cryptocurrency Payments
14-day money-back guarantee

If you are not satisfied with the product, simply return it and we will refund your money

SKU: N/A Category:

N-Acetyl Selank Amidate serves as a valuable research tool for investigating enhanced anxiolytic mechanisms, prolonged cognitive modulation, and sustained neurotransmitter system effects in laboratory settings.

Research Disclaimer: Peptides.GG sells this and all other peptides for Research Only and not for human consumption.

Frequently Asked Questions About NA Selank Amidate

What is NA Selank Amidate?

N-Acetyl Selank Amidate (NA-Selank) is a modified synthetic heptapeptide - a second-generation analog of Selank (a tuftsin analog) with N-terminal acetylation and C-terminal amidation that improve metabolic stability and extend duration of activity. It is supplied strictly as a research compound for laboratory use and is not for human consumption.

What is the amino acid sequence of NA Selank Amidate?

NA-Selank has the sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂. Its molecular formula is C₃₅H₅₉N₁₁O₁₀, its molecular weight is 793.93 Da, and its CAS registry number is 864070-44-0. It carries an N-terminal acetyl group and a C-terminal amide that replace the free termini of unmodified Selank.

What is NA Selank Amidate studied for in research?

In preclinical and in vitro research, NA-Selank is used to investigate prolonged anxiolytic mechanisms and GABAergic modulation, sustained cognitive performance, chronic neuroprotection, extended neurotransmitter-system modulation, and stress resilience - leveraging its extended duration of action. Supplied for laboratory research use only; not for human consumption.

What modifications distinguish NA-Selank from Selank?

NA-Selank adds an N-terminal acetyl group, which blocks aminopeptidase attack, and a C-terminal amide, which prevents carboxypeptidase degradation. Together these terminal modifications substantially increase enzymatic stability - extending the plasma half-life from roughly 20-30 minutes for Selank to about 200-300 minutes - allowing researchers to study sustained effects with less frequent administration.

What size is NA Selank Amidate available in?

NA Selank Amidate is supplied as a lyophilized (freeze-dried) powder in 10 mg and 30 mg sizes. The lyophilized format limits solution-phase degradation during storage and allows precise gravimetric preparation of research concentrations at the point of use.

How is NA Selank Amidate stored and handled in the laboratory?

NA-Selank is a white to off-white lyophilized powder soluble in water, bacteriostatic water, and phosphate-buffered saline. The lyophilized powder is kept sealed, cold (-20°C to -80°C), and protected from light and moisture until use. Its terminal modifications give it enhanced stability relative to unmodified Selank. Each batch is third-party tested with a Certificate of Analysis.

Research Overview

N-Acetyl Selank Amidate serves as a valuable research tool for investigating enhanced anxiolytic mechanisms, prolonged cognitive modulation, and sustained neurotransmitter system effects in laboratory settings. This modified heptapeptide represents a second-generation analog of Selank, incorporating N-terminal acetylation (Ac-) and C-terminal amidation (-NH₂) to dramatically improve metabolic stability and extend duration of biological activity.

The peptide’s development focused on addressing the rapid enzymatic degradation that limits the duration of action of unmodified peptides. N-terminal acetylation blocks aminopeptidase attack, while C-terminal amidation prevents carboxypeptidase degradation, resulting in substantially extended plasma half-life and tissue persistence. Laboratory studies investigate NA-Selank’s effects on anxiety-related behaviors, cognitive performance markers, neurotransmitter systems, and stress response mechanisms in preclinical models.

NA-Selank research demonstrates pharmacological effects qualitatively similar to Selank but with markedly extended duration of action. Researchers investigating nootropic peptide mechanisms may also examine N-Acetyl Semax Amidate, another dual-modified peptide with complementary BDNF-upregulating and cognitive-enhancing research profiles. This enhanced stability profile allows researchers to investigate long-term modulation of neurotransmitter systems, sustained behavioral effects, and cumulative neuroplastic changes with simplified administration regimens in experimental protocols.

Molecular Characteristics

Complete Specifications:

  • CAS Registry Number: 864070-44-0
  • Molecular Weight: 793.93 Da
  • Molecular Formula: C₃₅H₅₉N₁₁O₁₀
  • Amino Acid Sequence: Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂
  • Peptide Classification: Modified synthetic tuftsin analog
  • Modifications: N-terminal acetylation, C-terminal amidation
  • Appearance: White to off-white lyophilized powder
  • Solubility: Water, bacteriostatic water, phosphate buffered saline
  • Net Charge: +2 at physiological pH

The peptide’s modified structure incorporates an acetyl group (CH₃CO-) at the N-terminus and an amide group (-NH₂) at the C-terminus, replacing the free amino and carboxyl groups present in unmodified Selank. These terminal modifications create a more lipophilic molecule with enhanced membrane permeability and resistance to enzymatic degradation. The core sequence maintains three proline residues and two basic amino acids (lysine, arginine) that contribute to biological activity and receptor interactions.

Pharmacokinetic Profile in Research Models

NA-Selank pharmacokinetic characterization in preclinical research reveals substantially enhanced properties compared to unmodified Selank:

Enhanced Stability Profile:

  • Plasma half-life: Approximately 200-300 minutes (vs. 20-30 minutes for Selank)
  • Enzymatic resistance: 8-10 fold increased stability vs. unmodified peptide
  • Brain tissue persistence: Extended detection in CNS tissue
  • Biological activity duration: Effects observed for 8-12 hours post-administration

Absorption and Distribution:

  • Multiple administration routes investigated: intranasal, subcutaneous, intraperitoneal
  • Blood-brain barrier penetration: Enhanced vs. unmodified Selank
  • Tissue distribution: Broader and more sustained tissue exposure
  • Peak plasma concentrations: 30-60 minutes post-administration

Metabolic Considerations:

  • Primary degradation: Slower enzymatic cleavage at internal peptide bonds
  • Metabolites: Similar profile to Selank but with delayed formation
  • Excretion: Primarily renal following metabolism

These enhanced pharmacokinetic characteristics enable research protocols with extended observation periods, reduced administration frequency, and investigation of cumulative effects over extended timeframes.

Research Applications

Extended Anxiolytic Mechanism Studies

NA-Selank serves as a research tool for investigating sustained anxiolytic mechanisms:

  • Prolonged GABAergic Modulation: Investigation of extended GABA system effects without tolerance development
  • Sustained Stress Response: Analysis of long-term HPA axis regulation and cortisol dynamics
  • Chronic Stress Models: Examination of repeated exposure paradigms with sustained anxiolytic activity
  • Circadian Rhythm Integration: Studies on anxiety behavior across multiple light/dark cycles
  • Long-Term Receptor Changes: Investigation of chronic receptor expression and sensitivity adaptations

Research protocols employ extended behavioral testing paradigms, serial neurochemical sampling, and longitudinal assessment of anxiety-related measures to characterize NA-Selank’s prolonged anxiolytic profile.

Sustained Cognitive Enhancement Research

Laboratory studies investigate NA-Selank in prolonged cognitive modulation research:

  • Multi-Day Learning Protocols: Investigation of sustained effects on acquisition and consolidation
  • Working Memory Research: Analysis of extended improvement in working memory performance
  • Attention Span Studies: Examination of sustained attention and vigilance over extended periods
  • Cognitive Endurance: Research on mental fatigue resistance and sustained cognitive performance
  • Neuroplasticity Investigations: Studies on cumulative effects on synaptic plasticity markers

Experimental models include multi-day cognitive testing batteries, chronic administration paradigms, and longitudinal assessment of cognitive performance to leverage NA-Selank’s extended duration of action.

Chronic Neuroprotection Research

Research applications extend to sustained neuroprotective mechanism investigation:

  • Cumulative Antioxidant Effects: Examination of long-term oxidative stress reduction
  • Sustained Anti-Inflammatory Activity: Investigation of chronic neuroinflammation modulation
  • Repeated Injury Models: Studies on protection against repeated or ongoing neural insults
  • Neurodegenerative Models: Research in chronic progressive neurodegeneration paradigms
  • Long-Term Neurotrophic Support: Investigation of sustained BDNF and growth factor expression

Laboratory protocols investigate NA-Selank’s neuroprotective effects in chronic exposure models, repeated injury paradigms, and long-term neurodegeneration studies where sustained activity provides experimental advantages.

Prolonged Neurotransmitter Modulation

NA-Selank provides a research tool for investigating extended neurotransmitter system effects:

  • Sustained Monoamine Levels: Studies on prolonged serotonin, dopamine, and norepinephrine modulation
  • Chronic Enzyme Expression: Investigation of long-term changes in metabolic enzyme expression
  • Receptor Adaptation Research: Analysis of receptor sensitivity and density changes with chronic exposure
  • Synaptic Remodeling: Research on structural synaptic changes with sustained neurotransmitter modulation
  • Homeostatic Plasticity: Investigation of compensatory mechanisms in response to prolonged modulation

Laboratory investigations examine NA-Selank’s extended effects through longitudinal neurochemical analysis, repeated behavioral assessment, and molecular analysis of chronic adaptations.

Stress Resilience Research

NA-Selank facilitates investigation of sustained stress resistance mechanisms:

  • Chronic Stress Paradigms: Research in repeated stress exposure models
  • Stress Recovery Studies: Investigation of accelerated recovery and resilience building
  • Behavioral Sensitization: Analysis of stress-induced behavioral sensitization prevention
  • Neuroendocrine Adaptation: Studies on HPA axis adaptation to chronic stress
  • Stress-Related Pathology: Research on prevention of stress-induced structural and functional changes

Research protocols examine NA-Selank’s effects in chronic unpredictable stress, repeated restraint stress, and other long-term stress paradigms where extended activity duration provides experimental utility.

Laboratory Handling and Storage Protocols

Lyophilized Powder Storage:

  • Store at -20°C to -80°C in original sealed vial
  • Protect from light exposure and moisture
  • Desiccated storage environment required
  • Stability data available for 12+ months at -20°C
  • Enhanced stability vs. unmodified Selank even in lyophilized form

Stability Advantages:
NA-Selank demonstrates significantly enhanced stability compared to unmodified Selank. The terminal modifications provide resistance to enzymatic degradation even at room temperature for short periods, though standard peptide handling protocols should still be followed.

Quality Assurance and Analytical Testing

Each NA-Selank batch undergoes comprehensive analytical characterization:

Purity Analysis:

  • High-Performance Liquid Chromatography (HPLC): ≥98% purity
  • Analytical method: Reversed-phase HPLC with UV detection at 214nm
  • Verification of acetylation and amidation modifications

Structural Verification:

  • Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms molecular weight 793.93 Da
  • Amino acid analysis: Verifies sequence composition
  • Terminal modification confirmation: Validates acetylation and amidation
  • Peptide content determination: Quantifies actual peptide content by weight

Contaminant Testing:

  • Bacterial endotoxin: <5 EU/mg (LAL method)
  • Heavy metals: Below detection limits per USP standards
  • Residual solvents: TFA and acetonitrile within acceptable limits
  • Water content: Karl Fischer titration (<8%)

Documentation:

  • Certificate of Analysis (COA) provided with each batch
  • Third-party analytical verification available upon request
  • Stability data documented for recommended storage conditions
  • Batch-specific QC results traceable by lot number

Research Considerations

Experimental Design Factors:

Researchers should consider several factors when designing NA-Selank experiments:

1. Extended Activity Profile: NA-Selank’s prolonged duration of action allows for once-daily or less frequent administration in research protocols, simplifying experimental design.

2. Concentration Selection: Due to enhanced potency and duration, lower effective concentrations may be appropriate compared to unmodified Selank. concentration-response relationships should be established.

3. Temporal Assessment: Design measurement timelines to capture extended effects. Assessment points at 4, 8, 12, and 24 hours may reveal sustained activity.

4. Chronic vs. Acute Paradigms: NA-Selank is particularly suited for chronic administration studies where sustained effects are desired.

5. Comparative Studies: Direct comparison with unmodified Selank can illuminate the specific advantages of terminal modifications.

Mechanism Investigation:

NA-Selank’s mechanisms of action are expected to parallel Selank but with extended temporal dynamics:

  • Prolonged GABAergic system modulation
  • Sustained monoamine neurotransmitter effects
  • Extended BDNF upregulation
  • Cumulative gene expression changes
  • Long-term synaptic plasticity effects — for comparison, the synthetic nootropic Noopept offers an alternative research approach to cognitive enhancement through distinct NGF and BDNF modulation pathways

The enhanced stability allows investigation of mechanisms requiring sustained peptide presence.

Compliance and Safety Information

Regulatory Status:
N-Acetyl Selank Amidate is provided as a research chemical for in-vitro laboratory studies and preclinical research only. This product has not been approved by the FDA for human therapeutic use, dietary supplementation, or medical applications.

Intended Use:

  • In-vitro cell culture studies
  • In-vivo preclinical research in approved animal models
  • Laboratory investigation of biological mechanisms
  • Academic and institutional research applications

NOT Intended For:

  • Human consumption or administration
  • Therapeutic treatment or diagnosis
  • Dietary supplementation
  • Veterinary therapeutic applications without appropriate oversight

Safety Protocols:
Researchers should follow standard laboratory safety practices when handling NA-Selank:

  • Use appropriate personal protective equipment (lab coat, gloves, safety glasses)
  • Handle in well-ventilated areas or fume hood
  • Follow institutional biosafety guidelines
  • Dispose of waste according to local regulations for biological/chemical waste
  • Consult material safety data sheet (MSDS) for additional safety information